VX-264
Vertex Lays Off 125 Staffers, Shrinks Rhode Island Campus After Diabetes Therapy Setback
Vertex Pharmaceuticals; layoffs; Rhode Island; diabetes therapy; VX-264; cell-device combo; clinical trial failure; facility consolidation
Back to the drawing board for Vertex’s ‘cells plus device’ diabetes programme
Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production
Vertexs second-generation diabetes cell therapy fails early-stage study
Failed, VX-264, Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880